|
TMDX | Transmedics Group, Inc. |
|
|
TMDX | Transmedics Group, Inc. |
| Electromedical & Electrotherapeutic Apparatus |
| Book value per $ invested | $ 0.09 |
| Leverage | 62.45% |
| Market Cap | $ 4.1B |
| PE | 44.28 |
| Dividend Yield | 0.00% |
| Profit | $ 91.5m |
| Margin | 16.29% |
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.